Prevention and Treatment of Pyrrolitinib-associated Diarrhea
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
In this study, patients taking pyrrolitinib alone or combined with pyrrolitinib were
recruited (170 cases of secondary prevention and 300 cases of non-secondary prevention).
Non-secondary prevention: Explore the recovery time of oral loperamide 4mg T.I.D. for
pyrrolitinib induced diarrhea of 1-2 degrees.
Secondary prevention: To explore the incidence of grade 3 and above diarrhea during
c1D1-C1D22 in patients with oral loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital